Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Recruiting · NCT04424719 · Interventional (participants receive a specific treatment) · Lead sponsor: Institut Curie
View the official record on ClinicalTrials.gov →Interventions studied
Blood test
What this trial is about
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient aged of 18 years or more.
- Patient with uveal melanoma with high metastatic relapse risk defined as :
- T2b/c/d ou ≥ T3,
- or chromosom 3 or chromosom 8 abnormality by CGH array.
- Completion of treatment of the primary tumor ≤ 2 months.
- Patient able to comply with the schedule of visits and blood samples of the study.
- Signed informed consent form or legal representative.
Exclusion criteria
- Patient without french social insurance.
- Any social, medical or psychological condition making the research process impossible.
Where it is running
1 location listed.
- Institut Curie - Paris, France